Biogen Inc. Common Stock (BIIB)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.94 (-0.60%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Biogen Inc. Common Stock (BIIB)
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Key Insights

Critical company metrics and information
  • Share Price

    $156.46
  • Market Cap

    $22.80 Billion
  • Total Outstanding Shares

    145.72 Million Shares
  • Total Employees

    7,570
  • Dividend

    No dividend
  • IPO Date

    September 17, 1991
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.biogen.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-643.30 Million
Exchange Gains/Losses$54.60 Million
Net Cash Flow From Financing Activities$-1.34 Billion
Net Cash Flow From Operating Activities$2.13 Billion
Net Cash Flow From Investing Activities$-1.43 Billion
Net Cash Flow$-588.70 Million
Net Cash Flow From Financing Activities, Continuing$-1.34 Billion
Net Cash Flow From Operating Activities, Continuing$2.13 Billion
Net Cash Flow From Investing Activities, Continuing$-1.43 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Noncontrolling Interest$-800,000.00
Interest Expense, Operating$261.80 Million
Net Income/Loss$1.61 Billion
Other Operating Expenses$3.02 Billion
Income/Loss From Continuing Operations Before Tax$1.91 Billion
Cost Of Revenue$2.35 Billion
Operating Income/Loss$1.91 Billion
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Average Shares$146.10 Million
Selling, General, and Administrative Expenses$2.33 Billion
Operating Expenses$5.36 Billion
Costs And Expenses$7.70 Billion
Benefits Costs and Expenses$7.70 Billion
Income Tax Expense/Benefit$291.70 Million
Gross Profit$7.26 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations After Tax$1.61 Billion
Basic Earnings Per Share$11.11
Income Tax Expense/Benefit, Deferred$-27.80 Million
Net Income/Loss Attributable To Parent$1.62 Billion
Basic Average Shares$145.50 Million
Diluted Earnings Per Share$11.07
Net Income/Loss Available To Common Stockholders, Basic$1.62 Billion
Revenues$9.61 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Intangible Assets$9.81 Billion
Assets$28.31 Billion
Noncurrent Assets$21.48 Billion
Liabilities$11.95 Billion
Other Non-current Assets$8.47 Billion
Current Assets$6.83 Billion
Fixed Assets$3.21 Billion
Liabilities And Equity$28.31 Billion
Current Liabilities$5.42 Billion
Other Current Liabilities$4.71 Billion
Noncurrent Liabilities$6.53 Billion
Accounts Payable$422.70 Million
Equity Attributable To Parent$16.36 Billion
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$4.36 Billion
Wages$288.70 Million
Inventory$2.47 Billion
Equity$16.36 Billion
Long-term Debt$4.55 Billion
Other Non-current Liabilities$1.98 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Biogen Inc. Common Stock (BIIB)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.